US4792561A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors
Assignee: Syntex USA LLC
•
Filing: 1986-05-29
•
Granted: 1988-12-20
•
Expires: 2006-05-29
Abstract
Abstract The invention concerns a method of inhibiting both thromboxane synthetase and cyclic-AMP phosphodiesterase in a mammal having a disease characterized by elevated thromboxane levels or an imbalance of prostacyclin/thromboxane levels with a compound of the formula: <IMAGE> (I) or a pharmaceutically acceptable acid addition salt or ester thereof, wherein: X is chosen from the group consisting of: <IMAGE> and a covalent bond in which R1 is H, alkyl having 1-6 carbon atoms, optionally substituted phenyl or optionally substituted phenyl lower alkyl, when R2 is H or OH, or R1 and R2 taken together represent oxo, alkylidene having 1-6 carbon atoms or optionally substituted benzylidene; R3 is H or alkyl having 1-6 carbon atoms, R4 is H and R3 and R4 are either cis or trans to each other, or R3 and R4 taken together represent a covalent bond; n is an integer from 0-3; Het is 1-imidazolyl or 3-pyridyl; and the dotted line represents an optional covalent bond.
Inventors
- 👤 Keith A. M. Walker
- 👤 John J. Bruno
- 👤 Gregory R. Martinez
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 04:19
CPC Classifications
C; C07; C07D; C07D231/00; C07D231/02; C07D231/10; C07D231/12; C07D233/00; C07D233/54; C07D233/56; C07D249/00; C07D249/02; C07D249/08; C07D401/00; C07D401/02; C07D401/04; C07D401/06
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
166 words
A compound of the formula: ##STR39## or a pharmaceutically acceptable acid addition salt or ester thereof, wherein: X is chosen from the group consisting of: ##STR40## in which R 1 is H when R 2 is OH, or R 1 is phenyl or phenyl lower alkyl when R 2 is H or OH, wherein the phenyl radical is optionally monosubstituted with lower alkyl, lower alkoxy, hydroxy, trifluoromethyl or halogen, or R 1 and R 2 taken together represents oxo, alkylidene having 1-6 carbon atoms or optionally substituted benzylidene wherein the phenyl radical of the benzylidene group is optionally monosubstituted with lower alkyl, lower alkoxy, hydroxy, trifluoromethyl or halogen; R 3 is H or alkyl having 1-6 carbon atoms, R 4 is H and R 3 and R 4 are either cis or trans to each other, or R 3 and R 4 taken together represent a covalent bond; n is an integer from 0-3; Het is 1-imidazolyl; and the dotted line represents an optional covalent bond.
Claim 2
Dependent Claim
166 words
A compound of the formula: ##STR39## or a pharmaceutically acceptable acid addition salt or ester thereof, wherein: X is chosen from the group consisting of: ##STR40## in which R 1 is H when R 2 is OH, or R 1 is phenyl or phenyl lower alkyl when R 2 is H or OH, wherein the phenyl radical is optionally monosubstituted with lower alkyl, lower alkoxy, hydroxy, trifluoromethyl or halogen, or R 1 and R 2 taken together represents oxo, alkylidene having 1-6 carbon atoms or optionally substituted benzylidene wherein the phenyl radical of the benzylidene group is optionally monosubstituted with lower alkyl, lower alkoxy, hydroxy, trifluoromethyl or halogen; R 3 is H or alkyl having 1-6 carbon atoms, R 4 is H and R 3 and R 4 are either cis or trans to each other, or R 3 and R 4 taken together represent a covalent bond; n is an integer from 0-3; Het is 1-imidazolyl; and the dotted line represents an optional covalent bond.
Claim 3
Dependent Claim
9 words
The compound of claim 1, wherein X is ##STR41##
Claim 4
Dependent Claim
26 words
The compound of claim 2, wherein R 1 and R 2 taken together represent alkylidene having 1-3 carbon atoms and n is an integer from 1-3.
Claim 5
Dependent Claim
18 words
The compound of claim 2, wherein R 1 is phenyl, R 2 is H and n is 0.
Claim 6
Dependent Claim
24 words
The compound of claim 4, wherein R 1 is phenyl and the optional covalent bond represented by the dotted line is absent, namely 6-[phenyl(imidazol-1-yl)methyl]-3,4-dihydrocarbostyril.
Claim 7
Dependent Claim
24 words
The compound of claim 4, wherein R 1 is phenyl and the optional covalent bond represented by the dotted line is present, namely 6-[phenyl(imidazol-1-yl)methyl]carbostyril.
Claim 8
Dependent Claim
15 words
The compound of claim 1, wherein X is ##STR42## and n is 0 or 1.
Claim 9
Dependent Claim
17 words
The compound of claim 7, wherein R 3 and R 4 taken together represent a covalent bond.
Claim 10
Dependent Claim
22 words
The compound of claim 7, wherein R 3 is H or lower alkyl having 1-3 carbon atoms and R 4 is H.
Claim 11
Dependent Claim
27 words
The compound of claim 9, wherein R 3 is methyl, n is 0 and the optional covalent bond represented by the dotted line is absent, namely 6-[1-methyl-2-(imidazol-1-yl)ethenyl]-3,4-dihydrocarbostyril.
Claim 12
Dependent Claim
27 words
The compound of claim 9, wherein R 3 is H, n is 0 and the optional covalent bond represented by the dotted line is absent, namely 6-[2-(imidazol-1-yl)ethenyl]-3,4-dihydrocarbostyril.
Claim 13
Dependent Claim
27 words
The compound of claim 9, wherein R 3 is H, n is 0 and the optional covalent bond represented by the dotted line is present, namely 6-[2-(imidazol-1-yl)ethenyl]carbostyril.
Claim 14
Dependent Claim
26 words
The compound of claim 9, wherein R 3 is H, n is 1 and the optional covalent represented by the dotted line is absent, namely 6-[3-(imidazol-1-yl)prop-1-en-1-yl]-3,4-dihydrocarbostyril.
Claim 15
Dependent Claim
43 words
A pharmaceutical composition for administration to a mammal having a disease characterized by elevated thromboxane levels or an imbalance of prostacyclin/thromboxane levels, which comprises a therapeutically effective amount of a compound of claim 1 in admixture with one or more pharmaceutically acceptable excipients.
References Cited (Backward Citations)
US3962445A
Cited
JPS51125291A
Cited
JPS51118772A
Cited
JPS51136678A
Cited
JPS52283A
Cited
JPS5412384A
Cited
JPS5576872A
Cited
JPS5583749A
Cited
US4309432A
Cited
US4482560A
Cited
US4455422A
Cited
US4442106A
Cited
US4487772A
Cited
JPS57154129A
Cited
JPS57159778A
Cited
US4359475A
Cited
JPS58148817A
Cited
JPS58148861A
Cited
US4530930A
Cited
JPS5993050A
Cited
JPS5993052A
Cited
EP0148623A2
Cited
EP0166533A1
Cited
US4728653A
Cited
US4608388A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-12-20 | 1992-06-20 | 1992-12-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-12-20 | 1996-06-20 | 1996-12-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-12-20 | 2000-06-20 | 2000-12-20 | $7700.00 | Window Closed / Lapsed |